The GLP-1 Drug Landscape Changes on Thursday
The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer be permitted to be sold—creating a possible problem for the Americans who’ve come to rely on the generally cheaper option. The FDA in February announced that the shortage of the active ingredient…